Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

March 30, 2026

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

March 30, 2026

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

March 30, 2026

Paraganglioma Market Trends and Investment Opportunities 2026-2030

March 30, 2026

Brian Ferdinand Joins Forbes Finance Council, Marking Key Milestone for EverForward Trading

March 30, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » King Faisal Specialist Hospital & Research Centre Holds Firm as Global and Regional Healthcare Leader
Press Release

King Faisal Specialist Hospital & Research Centre Holds Firm as Global and Regional Healthcare Leader

By News RoomFebruary 15, 20243 Mins Read
King Faisal Specialist Hospital & Research Centre Holds Firm as Global and Regional Healthcare Leader
Share
Facebook Twitter LinkedIn Pinterest Email

RIYADH, Saudi Arabia, Feb. 15, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has once again secured its position for the second consecutive year as a global leader in healthcare and number one in the Middle East and Africa, ranking 20th globally among the leading healthcare institutions in the Brand Finance Global Top 250 Hospitals 2024 report. KFSH&RC continues to stand at the forefront both locally and regionally, underlining its commitment to delivering world-class patient-centric healthcare and medical innovation.

Leading the way, KFSH&RC is joined by King Saud Medical City, King Khalid University Hospital, National Guard Health Affairs, and King Fahd Medical City, all ranked among the top 100 globally. While King Fahd University Hospital and King Abdullah Medical City rank between 101 and 250. This assessment is based on insights from thousands of healthcare practitioners across over 30 countries.

The remarkable performance of KFSH&RC in this global ranking is a testament to the Kingdom’s healthcare transformation goals and the transformative impact of Vision 2030, reflected through the continuous improvement of healthcare services and the pursuit of technological advancements across the Kingdom for a healthier and thriving nation.

Brand Finance, founded in 1996, annually evaluates over 500 hospitals worldwide, utilizing more than 30 performance indicators encompassing healthcare, research centres, and education to support science-based strategic decision making.

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced hub for medical research and education. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally. Additionally, in 2022, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1cab7add-5d3e-482c-bd5b-cc8856cf7875


Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

General (Ret.) Frank McKenzie, Former CENTCOM Commander, Joins Pallas Speakers Bureau

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Paraganglioma Market Trends and Investment Opportunities 2026-2030

Brian Ferdinand Joins Forbes Finance Council, Marking Key Milestone for EverForward Trading

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 – Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

$28+ Billion Cancer Supportive Care Products Market Outlook Report, 2030

Trends and Opportunities in the Chemotherapy-At-Home Services Market, 2026-2030: Total Revenue to Grow by $1 Billion, Led by CVS Health, Optum, and Fresenius Kabi

Editors Picks

MEXC Lists 20 New Ondo Tokenized Stocks with Zero-Fee Trading

March 30, 2026

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

March 30, 2026

Paraganglioma Market Trends and Investment Opportunities 2026-2030

March 30, 2026

Brian Ferdinand Joins Forbes Finance Council, Marking Key Milestone for EverForward Trading

March 30, 2026

Latest News

Neuroblastoma Market Analysis Report 2026-2030 | Rising Childhood Cancer Incidence Fuels Demand | Identify Lucrative Growth Segments for Investment Purposes

March 30, 2026

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 – Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

March 30, 2026

$28+ Billion Cancer Supportive Care Products Market Outlook Report, 2030

March 30, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version